Janus Henderson Group PLC Has $26.74 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Janus Henderson Group PLC lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 35.6% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 178,954 shares of the biopharmaceutical company’s stock after selling 99,127 shares during the period. Janus Henderson Group PLC owned approximately 0.14% of Alnylam Pharmaceuticals worth $26,742,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in ALNY. Norges Bank acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $390,438,000. Capital International Investors grew its stake in Alnylam Pharmaceuticals by 15.8% in the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after acquiring an additional 488,814 shares during the period. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after buying an additional 287,064 shares during the last quarter. Capital Research Global Investors boosted its position in shares of Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after buying an additional 214,908 shares during the last quarter. Finally, abrdn plc boosted its position in shares of Alnylam Pharmaceuticals by 910.7% during the fourth quarter. abrdn plc now owns 232,716 shares of the biopharmaceutical company’s stock valued at $44,544,000 after buying an additional 209,691 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 32,450 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now directly owns 136 shares in the company, valued at approximately $30,013.84. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Yvonne Greenstreet sold 8,301 shares of the business’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the transaction, the chief executive officer now directly owns 80,534 shares in the company, valued at $18,602,548.66. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director David E. I. Pyott sold 32,450 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the transaction, the director now owns 136 shares of the company’s stock, valued at $30,013.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,450 shares of company stock worth $15,287,984. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded up $4.21 during mid-day trading on Wednesday, hitting $238.02. The stock had a trading volume of 261,139 shares, compared to its average volume of 872,706. The firm has a market cap of $30.11 billion, a P/E ratio of -87.24 and a beta of 0.37. The business has a fifty day moving average price of $202.39 and a 200-day moving average price of $172.99. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $263.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to the consensus estimate of $428.01 million. During the same quarter in the previous year, the firm posted ($1.40) earnings per share. The business’s revenue for the quarter was up 54.8% compared to the same quarter last year. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALNY has been the topic of several analyst reports. Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the company a “buy” rating in a research report on Monday, June 24th. SVB Leerink lifted their target price on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research report on Tuesday, June 25th. Citigroup lifted their target price on Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Canaccord Genuity Group lifted their target price on Alnylam Pharmaceuticals from $283.00 to $357.00 and gave the company a “buy” rating in a research report on Monday, July 8th. Finally, Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the company an “equal weight” rating in a research report on Tuesday, June 25th. Eight analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.73.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.